对喘生物药物的严重过敏反应的风险:基于全球真实世界数据库的药监测研究
Sunny Park1, Yeju Kim2, Geon Ho Lee2
1College of Pharmacy and Research Institute of Pharmaceutical Sciences, Korea University, Sejong, South Korea.
Scientific reports
|October 17, 2023
概括
治疗严重喘的生物疗法,包括奥马利祖马布,本拉利祖马布和梅波利祖马布,显示过敏反应的风险更高. 建议对这些喘药物进行仔细的治疗后监测.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药物监督 药物监督 药物监督
背景情况:
- 喘是一种慢性呼吸道炎症疾病.
- 严重的喘往往需要口服葡萄糖皮质激素治疗,与不良事件有关.
- 生物学家提供替代性喘治疗,包括奥马利祖马布,本拉利祖马布,梅波利祖马布,复利祖马布和杜比卢马布.
研究的目的:
- 评估与五种生物性喘疗法相关的过敏反应风险.
- 分析针对不良事件的个体病例报告的大型全球数据库.
主要方法:
- 利用了来自乌普萨拉监测中心 (1968-2019) 的个人病例报告.
- 在所有药物和单克隆抗体中进行了不成比例分析.
- 通过使用标准化的MedDRA查询来定义过敏反应.
主要成果:
- 奥马利祖马布,本拉利祖马布和梅波利祖马布显示了对过敏反应的积极信号.
- 杜皮卢马布在过敏反应方面没有显示出类似的信号.
- 由于报告的病例有限,reslizumab需要更多的数据.
- 大多数确定的过敏反应 (96.2%) 是严重的.
结论:
- 奥马利祖马布,本拉利祖马布和梅波利祖马布与喘患者过敏反应的高风险有关.
- 建议在这些生物制剂的管理后期提高警.
- 需要进一步研究reslizumab的过敏反应风险概况.
相关概念视频
Allergic Reactions
27.6K
Overview
27.6K
Allergic Drug Reactions
852
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
852
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
312
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
312
Antiasthma Drugs: β2-Adrenoceptor Agonists
278
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
278
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Antiasthma Drugs: Leukotriene Modifiers
324
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
324


